GenStar: A method for de novo drug design

SummaryA novel method, which we call GenStar, has been developed to suggest chemically reasonable structures which fill the active sites of enzymes. The proposed molecules provide good steric contact with the enzyme and exist in low-energy conformations. These structures are composed entirely of sp3 carbons which are grown sequentially, but which can also branch or form rings. User-selected enzyme seed atoms may be used to determine the area in which structure generation begins. Alternatively, GenStar may begin with a predocked ‘inhibitor core’ from which atoms are grown. For each new atom generated by the program, several hundred candidate positions representing a range of reasonable bond lengths, bond angles, and torsion angles are considered. Each of these candidates is scored, based on a simple enzyme contact model. The selected position is chosen at random from among the highest scoring cases. Duplicate structures may be removed using a variety of criteria. The compounds may be energy minimized and displayed using standard modeling programs. Also, it is possible to analyze the collection of all structures created by GenStar and locate binding motifs for common fragments such as benzene and naphthylene. Tests of the method using HIV protease, FK506 binding protein (FKBP-12) and human carbonic anhydrase (HCA-II) demonstrated that structures similar to known potent inhibitors may be generated with GenStar.

[1]  P M Dean,et al.  Automated site-directed drug design : the prediction and observation of ligand point positions at hydrogen-bonding regions on protein surfaces , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[2]  J M Blaney,et al.  Molecular modeling software and methods for medicinal chemistry. , 1990, Journal of medicinal chemistry.

[3]  T A Jones,et al.  Refined structure of human carbonic anhydrase II at 2.0 Å resolution , 1988, Proteins.

[4]  B Honig,et al.  Internal cavities and buried waters in globular proteins. , 1986, Biochemistry.

[5]  Mark A. Murcko,et al.  Rotational barriers. 2. Energies of alkane rotamers. An examination of gauche interactions , 1988 .

[6]  A. Fersht,et al.  Energetics of complementary side-chain packing in a protein hydrophobic core. , 1989, Biochemistry.

[7]  G. Rose,et al.  Molecular recognition. I. Automatic identification of topographic surface features , 1985, Biopolymers.

[8]  R. Sheridan,et al.  Searching for pharmacophores in large coordinate data bases and its use in drug design. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[10]  P. Dean,et al.  Molecular Foundations of Drug-Receptor Interaction , 1987 .

[11]  Yvonne C. Martin.  Computer design of potentially bioactive molecules by geometric searching with ALADDIN , 1990 .

[12]  P R Connelly,et al.  Heat capacity changes and hydrophobic interactions in the binding of FK506 and rapamycin to the FK506 binding protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Privalov,et al.  Stability of protein structure and hydrophobic interaction. , 1988, Advances in protein chemistry.

[14]  G. Marshall.  Computer-aided drug design. , 1987, Annual review of pharmacology and toxicology.

[15]  B Honig,et al.  Extracting hydrophobic free energies from experimental data: relationship to protein folding and theoretical models. , 1991, Biochemistry.

[16]  R. Wade,et al.  New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. , 1989, Journal of medicinal chemistry.

[17]  Stephen R. Wilson,et al.  Calculation of rotational states of flexible molecules using simulated annealing , 1991 .

[18]  Olga Kennard,et al.  Systematic analysis of structural data as a research technique in organic chemistry , 1983 .

[19]  T. Maren,et al.  Carbonic anhydrase: General perspective and advances in glaucoma research , 1987 .

[20]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[21]  Patrick Argos,et al.  [10] Prediction of protein structure , 1986 .

[22]  Bernard Testa,et al.  X-ray crystallography and drug action: edited by A. S. Horn and C. J. De Ranter, Oxford University Press, 1984. £30.00 (xii + 514 pages) ISBN 0 19 855185 1 , 1985 .

[23]  Anna Tempczyk,et al.  Electrostatic contributions to solvation energies: comparison of free energy perturbation and continuum calculations , 1991 .

[24]  M. Lawrence,et al.  CLIX: A search algorithm for finding novel ligands capable of binding proteins of known three‐dimensional structure , 1992, Proteins.

[25]  Conrad C. Huang,et al.  Automated site-directed drug design using molecular lattices , 1992 .

[26]  I. Kuntz,et al.  Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. , 1988, Journal of medicinal chemistry.

[27]  G. Petsko,et al.  Weakly polar interactions in proteins. , 1988, Advances in protein chemistry.

[28]  I. Kuntz,et al.  Docking flexible ligands to macromolecular receptors by molecular shape. , 1986, Journal of medicinal chemistry.

[29]  P. Privalov,et al.  The hydrophobic effect: a reappraisal , 1989 .

[30]  A. M. Lesk,et al.  Molecular speleology: the exploration of crevices in proteins for prediction of binding sites, design of drugs and analysis of surface recognition , 1986 .

[31]  A Wlodawer,et al.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Richard A. Lewis,et al.  Automated site-directed drug design: the concept of spacer skeletons for primary structure generation , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[33]  D Eisenberg,et al.  Where metal ions bind in proteins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J J Baldwin,et al.  Carbonic anhydrase inhibitors for the treatment of glaucoma , 2023, Медицинская этика.

[35]  Richard A. Lewis.  Automated site-directed drug design: Approaches to the formation of 3D molecular graphs , 1990, J. Comput. Aided Mol. Des..

[36]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[37]  W. Howe,et al.  Computer design of bioactive molecules: A method for receptor‐based de novo ligand design , 1991, Proteins.

[38]  R F Standaert,et al.  Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex , 1991, Science.

[39]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[40]  Robert B. Hermann,et al.  Theory of hydrophobic bonding. II. Correlation of hydrocarbon solubility in water with solvent cavity surface area , 1972 .

[41]  Michael K. Gilson,et al.  The inclusion of electrostatic hydration energies in molecular mechanics calculations , 1991, J. Comput. Aided Mol. Des..

[42]  Peter Gund,et al.  Chapter 27 Molecular Modeling as an Aid to Drug Design and Discovery , 1987 .

[43]  Holger Wallmeier,et al.  Computer‐Assisted Molecular Design (CAMD)—An Overview , 1987 .

[44]  P A Kollman,et al.  Electrostatic potentials of proteins. 1. Carboxypeptidase A. , 1976, Journal of the American Chemical Society.

[45]  Yvonne C. Martin,et al.  ALADDIN: An integrated tool for computer-assisted molecular design and pharmacophore recognition from geometric, steric, and substructure searching of three-dimensional molecular structures , 1989, J. Comput. Aided Mol. Des..

[46]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[47]  S. Fesik,et al.  NMR studies of molecular complexes as a tool in drug design. , 1991, Journal of medicinal chemistry.

[48]  Anders Liljas,et al.  Crystallographic studies of inhibitor binding sites in human carbonic anhydrase II: A pentacoordinated binding of the SCN− ion to the zinc at high pH , 1990, Proteins.

[49]  S. Yue.  Distance-constrained molecular docking by simulated annealing. , 1990, Protein Engineering.

[50]  F. A. Quiocho,et al.  Substrate specificity and affinity of a protein modulated by bound water molecules , 1989, Nature.

[51]  Paul A. Bartlett,et al.  CAVEAT: A program to facilitate the design of organic molecules , 1994, J. Comput. Aided Mol. Des..

[52]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[53]  J M Thornton,et al.  A novel method for the modelling of peptide ligands to their receptors. , 1991, Protein engineering.

[54]  C. Tanford,et al.  Empirical correlation between hydrophobic free energy and aqueous cavity surface area. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Pavel Hobza,et al.  Theoretical and experimental studies of biologically important hydrogen bonds , 1984 .

[56]  Richard A. Lewis,et al.  Automated site-directed drug design : the formation of molecular templates in primary structure generation , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[57]  M. L. Connolly.  Solvent-accessible surfaces of proteins and nucleic acids. , 1983, Science.

[58]  T. L. Blundell,et al.  Knowledge-based prediction of protein structures and the design of novel molecules , 1987, Nature.

[59]  G. M. Smith,et al.  Electronic distributions within protein phenylalanine aromatic rings are reflected by the three-dimensional oxygen atom environments. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[60]  P M Dean,et al.  Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogen-bonding regions at protein surfaces , 1989, Proceedings of the Royal Society of London. B. Biological Sciences.

[61]  Mark A. Murcko,et al.  Use of structural information in drug design , 1992, Current Biology.

[62]  M. Karplus,et al.  Crystallographic R Factor Refinement by Molecular Dynamics , 1987, Science.

[63]  B. Matthews,et al.  Response of a protein structure to cavity-creating mutations and its relation to the hydrophobic effect. , 1992, Science.

[64]  Stuart L. Schreiber,et al.  Atomic Structure of the Rapamycin Human Immunophilin FKBP-12 Complex , 1991 .

[65]  Richard H. Lathrop,et al.  ARIADNE: pattern-directed inference and hierarchical abstraction in protein structure recognition , 1987, CACM.

[66]  W E Stites,et al.  Contributions of the large hydrophobic amino acids to the stability of staphylococcal nuclease. , 1990, Biochemistry.

[67]  John Homer,et al.  Polyatomic London dispersion forces , 1987 .

[68]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[69]  M Lebl,et al.  Proton n.m.r. spectroscopic evidence for sulfur-aromatic interactions in peptides. , 1987, International journal of peptide and protein research.

[70]  C. Chothia.  The nature of the accessible and buried surfaces in proteins. , 1976, Journal of molecular biology.

[71]  A. Fersht,et al.  Contribution of hydrophobic interactions to protein stability , 1988, Nature.

[72]  M Karplus,et al.  Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin , 1991, Science.

[73]  Giuseppe Del Re,et al.  Towards a valence‐orbital/bond‐orbital description of biochemical H‐bonds from ab initio calculations , 1987 .

[74]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[75]  C. Sander,et al.  Database of homology‐derived protein structures and the structural meaning of sequence alignment , 1991, Proteins.

[76]  I. Kuntz,et al.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[77]  M. Fitzgibbon,et al.  Solution structure of the major binding protein for the immunosuppressant FK506 , 1991, Nature.

[78]  S. Freer,et al.  Design of enzyme inhibitors using iterative protein crystallographic analysis. , 1991, Journal of medicinal chemistry.

[79]  Akiko Itai,et al.  Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation , 1991 .

[80]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[81]  J. A. C. Rullmann,et al.  Atomic charge models for polypeptides derived from ab initio calculations , 1989 .

[82]  D. Goodsell,et al.  Automated docking of substrates to proteins by simulated annealing , 1990, Proteins.

[83]  G Náray-Szabó,et al.  Electrostatic complementarity in molecular associations. , 1989, Journal of molecular graphics.

[84]  Stanley J. Gill.  Thermodynamics of ligand binding to proteins , 1989 .

[85]  Charles Tanford,et al.  The hydrophobic effect , 1980 .

[86]  R J Leatherbarrow,et al.  Structure-activity relationships in engineered proteins: analysis of use of binding energy by linear free energy relationships. , 1987, Biochemistry.